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The 2nd Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) took place on 03–05
November 2017 in Detroit, Michigan, USA. This symposium was a joint meeting of the
Hidradenitis Suppurativa Foundation (HSF Inc.) founded in the USA, and the Canadian
Hidradenitis Suppurativa Foundation (CHSF). This was the second annual meeting of the SHSA
with experts from different disciplines arriving from North America, Europe and Australia, in a
joint aim to discuss most recent innovations, practical challenges and potential solutions to issues
related in the management and care of Hidradenitis Suppurativa patients. The last session involved
clinicians, patients and their families in an effort to educate them more about the disease.

Keywords
hidradenitis suppurativa; symposium
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INTRODUCTION
Symposium on Hidradenitis Suppurativa (HS) Advances 03–05 November 2017, Detroit,
MI, USA. The 2nd Annual Symposium on Hidradenitis Suppurativa Advances was held in
Detroit, Michigan from 3 November 2017 to 5 November 2017. This symposium was a joint
meeting of the Hidradenitis Suppurativa Foundation (HSF Inc., Santa Monica, CA, USA),
founded in the United States, and the Canadian Hidradenitis Suppurativa Foundation
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(CHSF).The conference was opened by Dr. Hamzavi, President of HSF, Dr. Marc Bourcier,
president of the CHSF.
The purpose of this meeting was to gather well-known researchers from different disciplines
to discuss the most recent innovations, practical challenges and potential solutions to issues
related to management and care of HS patients. Furthermore, in this meeting, HS patients
were involved and attended a HS School that was on the last day of our meeting.
A range of interactive educational sessions on the epidemiology, economic burden,
pathophysiology and management of HS were organized. This inaugural meeting was well
received by 125 attendees: 95 from Canada, 26 from United States and 4 internationals.
1.1 |

Background

Author Manuscript

Hidradenitis Suppurativa (HS) is a chronic, inflammatory, recurrent, debilitating skin disease
(of the terminal hair follicle) that usually presents after puberty with painful, deep-seated,
inflamed lesions in the apocrine gland-bearing areas of the body, most commonly the
axillary, inguinal and anogenital regions.[1] The disease has female preponderance [1] and
has a peak of onset in the second or third decades of life.[1–3] Despite the increased
awareness and scholarly attention to HS in the past recent years, HS is still delayed in
diagnosis of 7.2 years in average globally.[4] And there is still much more that we need to
learn about this disease regarding its pathophysiology, epidemiology and management.
Therefore, more research is required to assess the complexity of this disease and its
management.
HS Ultrasound Workshop (pre-conference)

Author Manuscript

The meeting also included an HS Ultrasound (US) Workshop, that took place in Henry Ford
Health Systems in Detroit, Michigan, USA. This US workshop was orchestrated by Dr.
Ximena Wortsman, Pontifical Catholic University, Santiago, Chile and Dr. Indermeet Kohli,
Henry Ford Hospital, Detroit, MI, USA. This was the first time that the workshop was
offered at the SHSA. During the workshop, lectures were given regarding basic ultrasound
concepts with an emphasis on ultrasound imaging of the skin in HS. Following didactics,
live patients kindly volunteered their time so over 20 trainees could practice what they had
learned.

2|

SCIENTIFIC SESSION 1

Author Manuscript

The conference was opened by Dr. Iltefat Hamzavi, president of HSF, and Dr. Marc
Bourcier, president of the CHSF.
2.1 |

Epidemiology and comorbidity of Hidradenitis Suppurativa
Dr. Joslyn Kirby from the USA chaired this panel discussion. Other participants were Dr.
Marc Bourcier, Dr. Amit Garg, Dr. Afsaneh Alavi, Dr. Vincent Piguet, Dr. Jerry Tan and Dr.
Ximena Wortsman.
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Unmet needs and Research gaps in HS

Author Manuscript

Marc Bourcier, Canada
Hidradenitis Suppurativa received a lot of attention in the past few years but still has a long
way to go. The development of a collaborative framework between healthcare professionals
dealing with this chronic and debilitating condition in North America provided a better
ground for research in this field. However, unmet needs and research gaps still exist in HS.
The main areas for research include early recognition of the disease, recognition of different
phenotype, the risk factors for disease progression and eventually management of the
disease.
2.3 |

Phenotypes, syndromic HS, co-morbidities
Afsaneh Alavi, Canada

Author Manuscript

HS presents in many ways, the variety of phenotypes including the typical and atypical
forms were discussed. Multiple attempts to classify HS phenotypes have been published in
the literature from latent class 1–3 and then 6 phenotypic classification such as classic,
scaring follicular, syndromic and ectopic type. Apparently not all HS patients are overweight
or obese, and BMI is another potential key for classification of HS. Insights into the genetic
background of the disease, various clinical presentation of the disease pathophysiology,
syndromic forms and highlights of the associated co-morbidities of HS were presented.
2.4 |

The incidence of HS in the US
Amit Garg, USA

Author Manuscript

The true incidence of HS is unknown, as is the utilization of dermatology specialists in the
care of HS patients. A retrospective analysis was performed on identified HS patients using
electronic health records data. The overall annual incidence of HS in the United States was
determined in this study to be 11.4 per 100 000, and more than twice in women than that of
men. A rare disease in the United States is defined as a disease that affects less than 200 000
individuals. The conclusion was that HS is an uncommon but not a rare disease.[5]
2.5 |

Identifying the True Burden of HS in the UK
Vincent Piguet, Canada

Author Manuscript

Limited data on the worldwide incidence and prevalence of HS is available, so the true
burden of the disease is uncertain. HS patients may be misdiagnosed, a common problem for
many patients with HS who often report that they are diagnosed only 5 to 10 years after the
start of the condition. Therefore, the group developed algorithms to identify unrecognized
“proxy” cases, with at least five Read code records for boils in flexural skin sites. His group
performed a UK population-based observational and case-control study on more than 4
million data records. Including “proxy” cases of HS, their results showed prevalence that is
closer to 1%. They concluded that this may be a “true” epidemiology of HS in the UK
population.[6]
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Patient oriented outcome measures in hidradenitis suppurativa
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Jerry Tan, Canada
This presentation focused on the role of patient reported outcome measures in clinical
research including quality-of-life measures. Unlike clinician reported outcome measures
which focus on clinical pathologic changes, patient reported outcomes focus on signs,
symptoms and impacts important to patients. Appropriate framing of duration for expected
improvement is also important in design of outcome measures. Currently available patient
reported outcome measures for HS include HSSA, HSIA,[7] HS-QoL[8] and HiSQoL (in
development). For each, methods in development and validation where available were
reviewed. In an effort to develop a unified quality-of-life instrument, HS-QoL has been
amalgamated with HiSQoL which currently consists of 10 domains and 43 items.

Author Manuscript

2.7 |
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Role of dermatologic ultrasound in HS
Ximena Wortsman, Chile
The objective of this lecture was to introduce the clinical application and utilization of
ultrasound in dermatology for HS. The clinical presentation of HS may be misleading, and
on sonography, more advanced signs of involvement may be detected. For example,
ultrasound studies may allow visualization of hidden tunnels or fistulous tracts and their
connections that the naked eye may not appreciate. Such ultrasonographic findings can
modify the staging of the patients; therefore, their management.[9] The presentation of HS
cases with clinical-sonographic correlations emphasized these points. This session was also
accompanied with a pre-conference workshop on ultrasound.

ORAL PRESENTATION 1: EPIDEMIOLOGY, CO-MORBIDITIES
Dr. Amit Garg from the USA chaired this session

3.1 | Accurate longitudinal lesion mapping in HS: Development of a standardized
mapping system for research and clinical use
John W. Frew, Australia

Author Manuscript

Current scoring systems of HS provide only a snapshot of the amount and variability of
lesion types at one point in time. Dr. Frew and his team have proposed a mapping approach
for HS lesions. They have developed a system that involves identification of anatomical
landmarks that may be documented in three dimensions utilizing ultrasound. This
longitudinal lesion mapping system for HS may be applicable for future use both clinically
and for research proposes.
3.2 |

The Canadian Population-based study of surgically managed HS
Morteza Bashash, Ali Mehdizadeh, Laura Rosella, Afsaneh Alavi (presenter, Canada), R.
Gary Sibbald, Delaram Farzanfar, Audrey Laporte, Howard Hu
HS is a chronic debilitating disease that poses also an economic burden to health systems.
However, limited studies have appraised the financial burden of this disease. This study was
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a population-based study of surgically managed HS in Canada based on international
classification of diseases (ICD-10) codes and Ontario Health Insurance Plan (OHIP) billing
codes between the years 2002 and 2013. A total of 6244 cases were included in this study.
Since the province of Ontario represents ethnically diverse population, the results may be
generalizable to other populations outside Canada. Two-thirds of the cases were between 30
and 64 years of age, and 66% were females; 76% of patients over 20 years of age had a high
school diploma, and a small subset (9%) lived in the rural neighbourhoods. 94% of patients
had moderate to high levels of morbidity, with more than half categorized as moderate. In
general, patients with HS impose higher costs at year 1. The first year includes the surgical
intervention and its associated costs, which also account for higher costs among men over 60
years of age. There are observed declines in the costs following the index date for both men
and women across all ages. For male patients, the annual costs ranged from 4570 to 23 118
CAD for patients under the age of 30 years and older than 65 years. The annual costs for
female patients ranged between 3976 to 14 520 CAD for patients under the age of 30 years
and older than 65 years.[10] So, the conclusion that can be drawn from this study is that
administrative population-based databases may provide essential information to assess the
burden of chronic diseases and may shed a light on factors associated with higher cost.[10]

Author Manuscript

3.3 | Effects of Resilience on depression and health-related quality of life for patients with
HS Coping with Hidradenitis
Melissa Butt, USA

Author Manuscript

Investigation on the coping strategies used by patients with HS to mitigate the effect of HS
and depression on quality of life. This was a multi-institutional cross-sectional survey of HS
patients at four international sites. Coping styles such as problem-focused and avoidant
styles were utilized more by those with a lower quality of life, suggesting that coping styles
plays an active role in HS quality of life. The conclusions were to focus on copying styles in
future studies, and to teach patients these techniques with the goal of increasing their quality
of life.[11]
3.4 | An Assessment of the relative impact of skin disease vs obesity on quality of life in
patients with HS
Nicole Mona Golbari (Presenter, USA), MA Storer, ML Porter, AB Kimball

Author Manuscript

A survey was conducted regarding the impact of obesity versus the skin disease itself on the
quality of life for HS patients. The study included 31 participants with the mean BMI of 39,
utilizing DLQI relevant to both conditions: The Hurley Stage distribution was I: 3%, II:
58%, III: 39%. The mean total impact for HS versus weight was 16.5 vs 10.3 (maximum of
24), respectively. When comparing individual questions relevant to HS versus weight, QoL
scores were all significantly higher for skin disease. The results showed that HS skin disease
itself conferred a greater impact on quality of life rather than the obesity.
3.5 |

The link between depression and inflammation in HS
Delaram Frazanfar, Yekta Dowlati, Lars French, Michelle Lowes, Afsaneh Alavi (presenter,
Canada)
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The prevalence of affective disorders such as depression and anxiety is particularly high in
autoimmune diseases including inflammatory dermatological conditions such as HS. A
literature review spanning across the fields of psychology, neuroscience and dermatology
was conducted to gather evidence for the role of inflammation in precipitation of affective
disorders in HS patients. Elevated levels of circulating cytokines such as interleukin-6 (IL-6)
and tumor necrosis factor alpha (TNF-alpha) may exhibit a dose-response pattern with
severity of depression.[12]
3.6 |

HS: The relationship between pain, depression, and quality of life
Zarine S. Patel (presenter, USA), Elizabeth K. Seng, Steven R. Cohen, Michelle A. Lowes

Author Manuscript

Pain and distress are core components of the HS experience.[13] This issue was investigated
in 201 patients from the Montefiore HS Treatment Center utilizing validated questionnaires.
Higher DLQI scores were strongly associated with lower SF-36 pain subscale scores Higher
DLQI scores, indicating greater impact on quality of life, were strongly associated with
lower SF-36 pain sub scale scores indicating below average health status related to bodily
pain and pain interference. The conclusion was that pain and depression are central to the
poor quality of life associated with HS.

4|

SESSION 2: PATHOPHYSIOLOGY OF HS
Dr. John W. Frew from Australia chaired this session.

4.1 |

Pathophysiology of Hidradenitis Suppurativa
Michelle A. Lowes, USA

Author Manuscript

The pathogenesis of HS is complex and not well understood.[14] This was an introduction of
what we currently know about the role of genes, cytokines, biofilms on pathogenesis and
their impact on disease activity. Environmental factors such as obesity and stress may also
promote and exacerbate the disease. The resultant chronic cutaneous suppurative
inflammation then recruits the systemic immune system. The primary cytokine signature of
HS is not yet known. However, IL-6 is a cytokine that may explain some of the systemic
manifestations of HS, including acute phase reactants, immunoglobulins, neutrophilia, fever,
as well as pain, depression and inflammatory arthritis. This is a unifying hypothesis to
integrate cutaneous and systemic inflammation in HS, but further studies are needed to
evaluate this concept.

Author Manuscript

4.2 | Genetics of HS: A systemic review and critical evaluation of reported sequence
variants in HS
John W. Frew, Australia
A systematic review of the literature was conducted for studies pertaining to genetic
investigations on the background of HS.[15] The large number of mutations of “uncertain
significance” is largely due to the variable number of functional studies.[15]
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Update on the role of bacteria and the skin microbiome in HS
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Haley Naik, USA
In recent years, sequence-based genomic approaches have been introduced to provide an
unbiased assessment of the microorganisms existing on the skin and mucosal surfaces in
health and disease. Microbes are believed to play an important role in initiating and
perpetuating HS. While conventional culture-based methods have been used to identify
microorganisms in HS lesions, they have failed to isolate organisms in 50% of HS lesions
because less than 1% of bacterial species are cultivatable under standard laboratory
conditions.
4.4 |

Biofilms in Hidradenitis Suppurativa
Gregory Schultz, USA

Author Manuscript

Recent data strongly indicate that bacterial biofilms play a major role in stimulating the
chronic inflammation that characterizes acute and chronic HS lesions. Commensal
organisms have been identified in tissues in either prolonged culture methods or in RNA
metagenomics sequencing. Biofilm bacterial structures have been histologically detected in a
high percentage of chronic lesions and in perilesional samples.[16]
4.5 |

The Critical role of alcohol in the pathogenesis of HS
Giovanni Damiani (presenter, Italy), Elena Pezzolo, Ilaria Coati, Nicola Milanesi, Simone
Ribero, Michela Iannone, Stefano Veraldi, Emilio Berti

Author Manuscript

The objective of this study was to determine the role of alcohol in HS patients’ lives. This
was a prospective observational study that enrolled HS patients for 3 months. The study was
conducted via questionnaires that included the Alcohol Use Disorders Identification Test
(AUDIT), DLQI and the Autoinflammatory Disease Damage Index (ADDI) and the
Sartorius Score. Participants in the study were shown a 10 minutes video that exhibited the
deleterious effects of alcohol. The results showed younger patients had higher AUDIT index
and lower ADDI and Sartorius scores that were mild to moderate. However, further studies
are required to assess whether alcohol plays any role in HS disease.
4.6 | Nicastrin Haploinsufficiency increases inflammatory responsiveness in
Keratinocytes cell lines
Elisha D.O. Roberson, USA

Author Manuscript

In some rare families with autosomal dominant HS, mutations in components of the gammasecretase complex have been previously identified. The most prevalent mechanism is
presumed to be loss-of-function of the Nicastrin subunit. ShRNA knockdown constructs
were developed for Nicastrin and their effects investigated on embryonic kidney cells and
immortalized keratinocytes. Non-radioactive proliferation assay was performed, and cells
that had less Nicastrin showed increased cell death. Furthermore, transcriptome profiling
with illumine bead arrays demonstrated significant keratinocyte alterations with Nicastrin
knockdown.
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Biomarkers in Hidradenitis Suppurativa

Author Manuscript

Lauren K Hoffman (presenter, USA), L. Tomalin, O. Lukatskaya, M. Suarez-Farinas, MA
Lowes
No diagnostic test exists for HS, nor have biomarkers been identified that reliably describe
disease activity. A literature review was conducted to assess the type of serum biomarkers
available in HS.[17] The results failed to exhibit a unique serum diagnostic biomarker for HS.
However, many mediators are associated with HS, including IL-32, IL-6, calprotectin
(S100A8/A9) and CRP. Hepcidin showed a 3-fold increase in HS patients and is also
involved in the pathogenesis of anaemia, which is also interesting since many HS patients
were found to suffer from chronic anaemia. Future studies should search deeper into the
pathogenesis of HS to reveal more about the disease and its biomarkers.

Author Manuscript

4.8 |

Epigenetic alteration by DNA hypermethylation of genes associated with HS
Uppala Radhakrishna, USA
HS displays genetic heterogeneity that may be traced to specific gamma-secretase gene
mutations in some families, whilst these gene mutations are not present in other sporadic
cases.[18] A genome-wide DNA methylation scan was performed in a cohort of 24 HS
subjects previously excluded from gamma-secretase mutations and 24 controls. A significant
CpG hypermethylation was detected at 304 genes in HS subjects.

4.9 |

Drug-Induced HS: A systematic review of case reports
John W. Frew, Australia

Author Manuscript

Rare reports of drug-induced HS do exist. In this study, all published cases were evaluated
using the Naranjo criteria. 18 publications reporting 48 individual case reports of HS were
identified. The most common incriminating drugs in decreasing order were Adalimumab,
Infliximab, Lithium, Etanercept, Rituximab, Vemurafenib and Tocilizumab. The overall
incidence for drug-induced HS was low, and the average Naranjo probability scores were
only “possible,” indicating the majority of cases had an alternative explanation for the
development of HS based upon known risk factors apart from the suggested medication.[19]
4.10 |

From Bank to bedside: Establishment of a fresh tissue bank for HS
Ginette A. Okoye, Angel S. Byrd (presenter, USA), Michelle L. Kerns, Carmelo CarmonaRivera, Philip M. Carlucci, Julie A. Caffrey, Stephen M. Milner, Justin M. Sacks, Oluseyi
Aliu, Lloyd S. Miller, Mariana J. Kaplan

Author Manuscript

This presentation described the establishment of a fresh tissue bank for HS. Tissue
resections can be harvested in the operation room as well as biopsies from patients in the
outpatient clinic. Tissue sections may be utilized for immunohistochemistry or
immunofluorescence, as well as a variety of other studies. The methods outlined in this
presentation are available in a companion online supplement, Specimen Collection for
Translational Studies in Hidradenitis Suppurativa. An example of utilization of tissues from
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the tissue bank is now published, titled, Collagen deposition in chronic Hidradenitis
Suppurativa: Potential role for CD163+ macrophages.[20]

5|

SESSION 3: MEDICAL TREATMENTS OF HS
Dr. Marc Bourcier from Canada chaired this session.

5.1 |

HS Treatment algorithm (focusing on medical treatment)
Dr. Joslyn Kirby, USA
A current HS treatment algorithm was presented that included a stage-based approach to
therapy that utilizes multimodal therapy.

Author Manuscript

5.2 |
why

Targeted antibiotic therapy combined with surgery for remission of HS: How and
Aude Nassif, France
Previous studies showed that broad spectrum antibiotics may induce long-term remission for
HS patients.[20,21] Targeted antibiotic therapy has been combined with surgery for remission
of HS. This study was performed by prospective evaluation of the bacteriology of HS lesions
based on Hurley severity score. Antibiotics were provided based on the results of the
isolated flora and clinical response observed. The results indicate relapses occurred without
appropriate maintenance therapy. Surgery was performed after “cooling down” the flares
with targeted antibiotics. The conclusion from this study was that targeted antibiotic therapy
can obtain remission in HS, but relapses demonstrate the need for subsequent surgery.

Author Manuscript

5.3 |

Antibiotic stewardship in HS
Mayur Ramesh, USA
A review of the role of bacteria in the pathogenesis of HS, the role of microbiota and biofilm
in HS, as well as potential adverse effects of long-term antibiotic use in HS.
This session was followed by a debate session.
Debate on the role of bacteria in HS

Author Manuscript

The pathophysiology of hidradenitis suppurativa (HS) is poorly understood, including the
role and contribution of microbes to HS pathogenesis. A debate was hosted focused on the
question of whether bacteria are infectious pathogens in HS. In general, the panelists agreed
that bacteria are pathogenic (defined as playing a role in pathogenesis), but there was
interesting discussion whether bacteria are causing HS as an infectious disease as we
classically understand it or whether bacteria might play a different role in HS pathogenesis.
5.4 |

TNF inhibitors in HS
Robert Micheletti, USA
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In this presentation, the available evidence supporting the use of TNFα inhibitors for
treatment of HS was reviewed. Advanced treatment pearls relevant to the use of anti-TNFα
therapy were also discussed. Infliximab and Adalimumab have shown the most promise
especially when administered in high dosage according to a systematic review from 2013.
Adalimumab was FDA approved based on the PIONEER study which was a breakthrough in
the management of HS.[22] Waning efficacy may be caused by the presence of anti-drug
antibodies. This phenomenon should be remembered and may be noticed with longer term
usage of this drug.
5.5 |

Hidradenitis Suppurativa in pregnancy
Jenny Hsaio, USA

Author Manuscript

HS commonly affects women of childbearing age. Pregnancy may either improve or worsen
HS symptoms. Pregnant women should receive the same lifestyle modification advice as
other HS patients such as smoking cessation and weight management. Most importantly,
medical treatment should obviously have minimal hazardous effects on the foetus.
Fortunately, many medications including biologic drugs are FDA pregnancy category B.
Medications that must be avoided during pregnancy in HS patients include retinoids,
tetracycline antibiotics and hormonal therapy (spironolactone and oral contraceptives).
Overall, the session focus on the close attention to the pregnant patient’s overall well-being,
as pregnancy can exacerbate conditions that have a higher incidence in HS patients,
including mood disorders and metabolic syndrome.
5.6 |

Emerging therapies in Hidradenitis Suppurativa

Steven Daveluy, USA present recent insights on emerging therapies in HS.

Author Manuscript
Author Manuscript

An increased scientific interest on HS, and increased annual number of publications, was
marked since the 1st International Conference on HS research, held in 2006 in Dessau,
Germany. This increased scientific interest together with activities of the HSF and the EHSF,
may have triggered much pharmaceutical interest, that was noticed for example in the
publication of the PIONEER study,[23] more studies are being published every year. Break
through publications with large numbers of patients have currently been published
originating from Europe and Israel, mostly under the auspices of the EHSF, reporting on
diagnostic criteria, the dynamic classification and treatment effectiveness evaluation score
IHS4, disease course, delay of diagnosis, stratification of obese vs. lean patients and several
others.[24–31] However, ongoing search for novel therapy is performed, examples of new
therapies for HS with positive results in small sample size studies include Ustekinumab
(IL-12/23 inhibitor), Secukinumab (IL-17A inhibitor), Anakinra (IL-1 inhibitor), Liraglutide
(a Glucagon-like peptide agonist) was published in a case report, Apremilast
(phosphodiesterase 4 inhibitor) was reported in a case series, and IFX1 (anti-C5a
monoclonal antibody). Overall, these agents show promising results, but larger randomized
controlled studies are required to further asses these novel therapies.

6|

ORAL PRESENTATION 3: MEDICAL TREATMENT OF HS
Dr. Robert Micheletti from the USA chaired this session.
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6.1 | The effect of chlorhexidine wash on antibacterial resistance in HS lesions: a
retrospective analysis
Dr. Paul Leiphart from the USA

Author Manuscript

The effects of chlorhexidine wash on antibacterial resistance in HS lesions were studied in a
cross-sectional analysis. A cross-sectional analysis was done on patients with HS at Penn
State Health from 2005 to 2017. The patients using a concomitant chlorhexidine wash while
taking antibiotics did have lower rates of resistance to macrolides (33.33% vs 50.00%),
clindamycin (0.00% vs 20.00%), cephalosporins (13.33% vs 44.44%), fluoroquinolones
(0.00% vs 5.71%), aminogly-cosides (0.00% vs 5.71%) and daptomycin (0.00% vs 10.00%)
than patients who were taking antibiotics without a concomitant chlorhexidine wash.
However, none of the differences in the patterns of antibacterial resistance were statistically
significant, regardless of the antibiotic class. Using a concomitant chlorhexidine cleanser
might decrease the rates of antibiotic resistance in HS lesions, however, we did not detect a
significant difference in the patterns of antibiotic resistance with or without the use of a
concomitant chlorhexidine cleanser.
6.2 |

Gender disparities in the onset of HS in children
Amanda F. Nahhas (presenter, USA), Cynthia L. Nicholson, Angela ParksMiller, Lauren
Gold, Iltefat Hamzavi

Author Manuscript

A retrospective chart review of 33 HS children was divided into 2 groups based on timing of
HS onset; prepubescent (n = 12) and post-pubescent (n = 21). In the younger group, there
were less females than males and the opposite was found in the older group. Hurley staging
and family history of HS did not appear to show significant differences when comparing
between prepubescent and postpubescent children with HS in this study.[32]
6.3 | Anti-inflammatory Benefit of Levofloxacin-Metronidazole-Rifampicin in the treatment
of HS
Lauren K. Hoffman (presenter, USA), YS Soliman, and SR Cohen

Author Manuscript

The efficacy of oral antibiotics alone or in combinations as treatment for HS has been shown
in previous studies. However, it is still uncertain whether this is due to anti-inflammatory
properties or antimicrobial effect or both. A retrospective chart review study of 19 HS
patients treated with the “triple antibiotic regimen” (Levofloxadn-MetronidazoleRifampicin) was performed. The duration of therapy was between 6 and 24 months. The
results showed nearly half of the patients experienced an improvement in pain and drainage
and 90% reported fewer HS flares.
6.4 |

A proof of concept study of the role of topical dapsone in patients with HS
Afsaneh Alavi, Jeannine A, Archer, Dalal Almutairi, Sharon A. Whitty, Monica Grewal,
Divine Joyce Briones and Eran Shavit (presenter, Canada)
Dapsone has been used in medicine for a myriad of conditions including HS. Topical
treatments in patients with HS have been a challenge and bacterial resistance is an issue with
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the commonly used topical clindamycin.[33] Topical dapsone is an FDA-approved
application for acne vulgaris.[34] A retrospective chart review of ten HS patients treated with
topical dapsone gel 5% was performed. The study was evaluated with patient satisfaction
questionnaires and dermatology life quality index (DLQI). This is a preliminary study as
recruitment is on-going. The initial results point to improved pain and overall satisfaction
with the use of topical dapsone gel. There is a need for randomized trial comparing the
effect of topical dapsone to placebo or standard treatment.
6.5 | Intralesional Triamcinolone, a standard of care treatment for Acute HS, does not
prove to be superior to placebo
Kristen D. Fajgenbaum (presenter, USA), Chris J. Sayed

Author Manuscript

Clinical experience and a single cohort study suggest that intralesional triamcinolone may be
useful for HS, but its effectiveness has not been extensively assessed. This aim of this study
was to assess the efficacy of intralesional triamcinolone at resolving lesions and decreasing
pain during acute flares. The study was designed as a randomized, double-blind, placebocontrolled trial comparing intralesional triamcinolone 10 mg/mL, triamcinolone 40 mg/mL,
and normal saline as a placebo control. A total of 58 patients were included in this study.
The results showed no significant difference between normal saline and intralesional
triamcinolone in both dosages in treating acute HS lesions.
6.6 |

A retrospective study of 39 HS patients treated with dapsone
Rashie Brar (presenter, Canada), Rosilene Lanzini, Hermenio Lima

Author Manuscript

The objectives of this study were to evaluate the effectiveness and adverse effects of
systemic dapsone as a single treatment or in combination with other regimens for HS. A
retrospective review of 39 HS patients was performed. Oral Dapsone was given either as
monotherapy (56%) or in combination with adalimumab (41%) and isotretinoin (2.6%). The
number of participants achieving clinical response using the reduction of the Hurley Stage
from the base line before treatment compared to the Hurley stage after treatment (min 6
months) was obtained. The improvement measurement was defined as at least reduction of
<=1 of the Hurley Stage in >=1 affected anatomic region with a minimum of 6 months of
therapy. Number of participants worsening, or no response was calculated using the increase
the Hurley Stage from the baseline before treatment compared to the Hurley stage after
treatment (min 6 months) or no change in the Hurley stage, respectively. The worsening of
HS was defined as at least increase by >= 1 Hurley Stage in >= 1 affected anatomic region
(minimum 6 months of therapy). Descriptive analysis was done using JMP® v.14.
Improvement was seen in all patients using dapsone for over 6 months. Larger studies are
required to assess the role of systemic dapsone, especially as monotherapy.

Author Manuscript
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SCIENTIFIC SESSION 4: MANAGEMENT OF HS
Dr. Michelle Lowes from the USA chaired this session.
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US evidence-based guidelines for HS treatment

Author Manuscript

Christopher Sayed, USA
Following the existing European guidelines for the management of HS,[35] the HS
Foundation and the Canadian HS Foundation joined forces to develop and publish the North
American guidelines for the management of HS. This work is ongoing with the goal of
publication in 2018.
7.2 |

Wound healing in HS
Hadar Lev-Tov, USA

Author Manuscript

HS is a disease that involves drainage and odour from the wounds. The daily management of
the wounds are essential to patients’ satisfaction and therefore to treatment success. What
kind of dressing should be utilized? How often should they be changed? For these and some
more unanswered questions, some practical pearls were presented for the everyday
management of chronic wounds in HS patients.
7.3 |

IDEOM: development of the core outcome set in HS
Dr. Amit Garg from the USA
Five e-Delphi rounds and four face-to-face consensus meetings were conducted to yield a
final core domain set which included; pain, physical signs, HS specific quality of life, global
assessment and progression of course.[36,37] Routine adoption of the core domains in future
HS trials should ensure that outcomes of importance to both patients and other relevant
stakeholders will be collected and will facilitate comparison of outcomes across trials.

Author Manuscript

7.4 |

NIAM: HS research
Dr. Ricardo Cibotti
In this session, Dr Cibotti, the Program Director of Immunobiology and Immune Diseases of
Skin Program in NIAM (National Institute of Arthritis and Musculoskeletal and Skin
Diseases) discussed the potential resources for skin research particularly HS.

7.5 |

HS Foundation (HSF) and research road map
Michelle Lowes, USA
Dr Michelle Lowes extensively discussed the road map of research planned by HSF. She
also discussed the unmet need to develop a North American HS consortium.

Author Manuscript
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SCIENTIFIC SESSION 5: SURGICAL TREATMENT OF HS
Dr. Iltefat Hamzavi from the USA chaired this session.

8.1 |

Office procedures for HS & the medical dermatologist
Christopher Sayed, USA
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HS unlike many other inflammatory dermatologic diseases is often surgically managed. The
patients are commonly referred to surgeons for interventions. However, some surgical
procedures for HS patients may be accomplished in office-based settings. The focus was on
deroofing and excisional procedures. Ideally, dermatologists’ will gain comfort approaching
certain procedures in selected cases for the benefit of the patients.
8.2 |

Where Mohs surgery meets HS
Richard Bennett, USA
Mohs surgery was developed and mainly utilized for the management of cutaneous
malignancy, particularly on the face region. This presentation was meant to introduce the
application of Mohs surgery in HS disease.

Author Manuscript

8.3 |

Complex surgical situations in the perianal and genital area
Falk Bechara, Germany
HS often requires surgical intervention for advance disease when the disease is under
medical control. The perianal and genital areas offer many challenges due to the anatomical
locations involved. Dr. Bechara shared his experience of some complex surgical situations in
these regions and has provided some important tips on how he was able to overcome these
obstacles.[38]

8.4 |

Plastic surgery for Hidradenitis Suppurativa
Aamir Siddiqui, USA

Author Manuscript

The role of plastic surgery for HS was presented through a retrospective review study on 254
patients. Reconstructive efforts were undertaken in 17% of procedures and represented skin
grafts or local flaps. For patients undergoing surgery while maintaining participation in the
multidisciplinary clinic, 87% of patients were healed at 1-year post surgery, whereas patients
who did not maintain follow-up in the multidisciplinary clinic only healed in 45%.
8.5 |

Lasers and light Therapies for the treatment of Hidradenitis Suppurativa
Iltefat Hamzavi, USA

Author Manuscript

Light and laser therapies have been utilized in the field of dermatology to treat a variety of
skin conditions, but only recently were studied in the management of HS. Laser and Light
therapies that are utilized for the treatment of HS offer several advantages including low risk
of complications in comparison to the traditional cold knife surgical procedures. As a
preventive and treatment option, laser-assisted hair reduction may be utilized for HS as well.
Also, photodynamic therapy (PDT) was introduced in the past few years for the management
of HS with promising results.[39] A surgical option includes tissue debulking with the CO2
laser (10 600nm wavelength).
8.6 |

Carbon Dioxide Laser surgery for Hidradenitis Suppurativa
Barry Resnik, USA

Exp Dermatol. Author manuscript; available in PMC 2019 July 01.

Shavit et al.

Page 16

Author Manuscript

Presented his experience with Carbon Dioxide (CO2) Laser excision for HS patients. In his
experience, this procedure was less painful, had a lower recurrence rate and resulted in scars
that were cosmetically pleasing for the patients.
HS School—The 2nd Symposium on Hidradenitis Suppurativa Advances (SHSA) held an
inaugural educational session especially for HS patients, called HS School.
HS School is an opportunity for patients and their caretakers or relatives to hear about HS
from experts, in language that the public can understand. There was also a Question and
Answer segment at the end of the session where patients can ask our panel general questions
about HS.
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